Arca
Skip to content

Hyperphosphatemia

Drug research and approvals for hyperphosphatemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 17, 2026, 9 studies of hyperphosphatemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, FDA has 1 approved and 3 open orphan designations naming it, and the EU has 3 authorised medicines for it.

  • Recruiting worldwide: 9
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 1
  • EU medicines: 3

Recruiting Now

Newest start dates first, of 9 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

4 approved, 3 in phase 3, 3 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition

Approved: Sevelamer, Ferric oxyhydroxide, Ferric citrate anhydrous, Colestilan chloride

Tenapanor
Phase 3 Sodium/hydrogen exchanger 3 inhibitor
Lanthanum carbonate
Phase 3 Phosphate sequestering agent
Sodium polystyrene sulfonate
Phase 1 Potassium sequestering agent

How Its Trials Ended

149 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 50 whose ending is known, 66% met their primary endpoint, 4% missed it and 30% stopped early.

  • Completed, result not reported7349%
  • Met its primary endpoint3322%
  • Status unknown149%
  • Ongoing128%
  • Stopped: other or unclear75%
  • Stopped: enrollment or feasibility53%
  • Stopped: funding32%
  • Missed its primary endpoint21%

FDA Orphan Designations

Approved first, then open designations, newest first
Dec 10, 1990Phos-LoTreatment of hyperphosphatemia in end stage renal failure.Fresenius Medical Care North AmericaApproved
Nov 14, 2023Tenapanor hydrochlorideTreatment of pediatric hyperphosphatemiaArdelyx, Inc.Designated
Jun 6, 1990Calcium carbonateTreatment of hyperphosphatemia in patients with end stage renal disease.R & D Laboratories, Inc.Designated
Jun 27, 1989Calcium acetateTreatment of hyperphosphatemia in end stage renal disease.Pharmedic CompanyDesignated

Medicines Authorised in the EU

Newest first
Jan 15, 2015Sevelamer carbonate Winthrop (previously Sevelamer carbonate Zentiva)Sevelamer carbonateSanofi Winthrop IndustrieEMA ↗
Aug 26, 2014VelphoroSucroferric oxyhydroxideVifor Fresenius Medical Care Renal Pharma FranceEMA ↗
Jun 9, 2009RenvelaSevelamer carbonateSanofi Winthrop IndustrieEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.